Hordur M Kolbeinsson1,2, Randa Preihs3, Alexandra Bengel3, Sreenivasa Chandana4, M Mura Assifi1,2,3, Mathew H Chung1,2,3, G Paul Wright1,2,3. 1. Spectrum Health General Surgery Residency, Grand Rapids, MI, USA. 2. Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, MI, USA. 3. Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, MI, USA. 4. Cancer and Hematology Centers of West Michigan, Grand Rapids, MI, USA.
Abstract
Background: The Kirsten rat sarcoma (KRAS) mutation predicts negative outcomes following resection of colorectal liver metastases (CRLM) and adjuvant hepatic arterial infusion (HAI) pump chemotherapy. Less is known on the effects of KRAS mutation on tumor response in patients with unresectable CRLM undergoing HAI chemotherapy with floxuridine. Methods: This is a retrospective cohort study investigating the effects of KRAS mutation on tumor response in patients with unresectable CRLM treated with HAI chemotherapy. Primary endpoint was objective response rate (ORR), secondary endpoints included overall tumor response and conversion to resectability. Results: Twenty-five patients with unresectable liver metastases from colorectal cancer were treated with HAI chemotherapy between 2017-2019. Median number of liver lesions was 12 (range, 1-59) and almost all (n=24) had prior chemotherapy before starting HAI therapy. Median number of cycles administered via HAI pump was 6 (range, 3-12). Overall decrease in liver tumor burden was 63.5% (median; range, -257-100%) with an ORR of 20/25 (80%) and 10 (40%) patients converting to resectable status. Eleven (44%) patients had KRAS positive tumors. When compared to wild-type, KRAS positive tumors had less overall percent decrease (58% vs. 70%; P=0.04) and ORR (7/11 vs. 13/13; P=0.03). Fewer patients with KRAS positive tumors converted to resectable status during HAI therapy (2/11 vs. 8/13; P=0.05). At a median follow-up of 14.6 months (range, 4.0-36.6 months), overall survival is 45% among KRAS-positive and 77% for wild type patients. Conclusions: KRAS mutational status in patients with unresectable liver metastases from colorectal cancer predicts worse response to HAI chemotherapy compared to wild type. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Background: The Kirsten rat sarcoma (KRAS) mutation predicts negative outcomes following resection of colorectal liver metastases (CRLM) and adjuvant hepatic arterial infusion (HAI) pump chemotherapy. Less is known on the effects of KRAS mutation on tumor response in patients with unresectable CRLM undergoing HAI chemotherapy with floxuridine. Methods: This is a retrospective cohort study investigating the effects of KRAS mutation on tumor response in patients with unresectable CRLM treated with HAI chemotherapy. Primary endpoint was objective response rate (ORR), secondary endpoints included overall tumor response and conversion to resectability. Results: Twenty-five patients with unresectable liver metastases from colorectal cancer were treated with HAI chemotherapy between 2017-2019. Median number of liver lesions was 12 (range, 1-59) and almost all (n=24) had prior chemotherapy before starting HAI therapy. Median number of cycles administered via HAI pump was 6 (range, 3-12). Overall decrease in liver tumor burden was 63.5% (median; range, -257-100%) with an ORR of 20/25 (80%) and 10 (40%) patients converting to resectable status. Eleven (44%) patients had KRAS positive tumors. When compared to wild-type, KRAS positive tumors had less overall percent decrease (58% vs. 70%; P=0.04) and ORR (7/11 vs. 13/13; P=0.03). Fewer patients with KRAS positive tumors converted to resectable status during HAI therapy (2/11 vs. 8/13; P=0.05). At a median follow-up of 14.6 months (range, 4.0-36.6 months), overall survival is 45% among KRAS-positive and 77% for wild type patients. Conclusions: KRAS mutational status in patients with unresectable liver metastases from colorectal cancer predicts worse response to HAI chemotherapy compared to wild type. 2022 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Mashaal Dhir; Heather L Jones; Yongli Shuai; Amber K Clifford; Samantha Perkins; Jennifer Steve; Melissa E Hogg; M Haroon A Choudry; James F Pingpank; Matthew P Holtzman; Herbert J Zeh; Nathan Bahary; David L Bartlett; Amer H Zureikat Journal: Ann Surg Oncol Date: 2016-07-18 Impact factor: 5.344
Authors: Rui Pedro Marques; Gonçalo S Duarte; Carmelo Sterrantino; Helena Luna Pais; António Quintela; Ana Paula Martins; João Costa Journal: Crit Rev Oncol Hematol Date: 2017-08-25 Impact factor: 6.312
Authors: Nancy E Kemeny; Donna Niedzwiecki; Donna R Hollis; Heinz-Josef Lenz; Robert S Warren; Michelle J Naughton; Jane C Weeks; Elin R Sigurdson; James E Herndon; Chunfeng Zhang; Robert J Mayer Journal: J Clin Oncol Date: 2006-02-27 Impact factor: 44.544
Authors: Gunnar Folprecht; Thomas Gruenberger; Wolf O Bechstein; Hans-Rudolf Raab; Florian Lordick; Jörg T Hartmann; Hauke Lang; Andrea Frilling; Jan Stoehlmacher; Jürgen Weitz; Ralf Konopke; Christian Stroszczynski; Torsten Liersch; Detlev Ockert; Thomas Herrmann; Eray Goekkurt; Fabio Parisi; Claus-Henning Köhne Journal: Lancet Oncol Date: 2009-11-26 Impact factor: 41.316
Authors: John B Ammori; Nancy E Kemeny; Yuman Fong; Andrea Cercek; Ronald P Dematteo; Peter J Allen; T Peter Kingham; Mithat Gonen; Philip B Paty; William R Jarnagin; Michael I D'Angelica Journal: Ann Surg Oncol Date: 2013-06-15 Impact factor: 5.344
Authors: James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica Journal: J Clin Oncol Date: 2007-10-10 Impact factor: 44.544